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journal	 supplement	 devoted	 to	 the	 investigation	 and	management	 of	 constipation	






Purpose: The	present	 is	 the	second	of	 these	reviews,	providing	contemporary	per-
spectives	and	clinical	challenges	regarding	behavioral,	conservative,	medical,	and	sur-
gical	treatments	for	patients	presenting	with	constipation.	It	includes	a	management	
algorithm to guide clinical practice.
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1  |  INTRODUC TION




to	 the	 investigation	 and	 management	 of	 constipation	 was	 pub-










this	 prevalent	 and	often	difficult-to-treat	 condition.	Areas	 for	 fu-
ture	 research	are	additionally	highlighted.	The	 first	 review	article	
addresses	 epidemiology,	 diagnosis,	 clinical	 associations,	 patho-
physiology,	 and	 investigation.	 This	 “sister”	 review	 addresses	 the	








2  |  BEHAVIOR AL AND CONSERVATIVE 
INTERVENTIONS












component	 to	 any	 educational	 initiative.	 Empathic	 reassurance	 is	
also	key	to	helping	the	patient	recognize	that	they	will	be	supported	
along their journey to improve compliance.

























a	significant	 increase	 in	stool	 frequency,	 from	2.9	stools	per	week	
at	baseline	to	3.8	after	treatment;	there	was	no	improvement	with	
placebo	 [17].	One	RCT	of	wheat	bran	 reported	 reduced	 straining,	
but	this	was	no	different	than	with	placebo	[18],	and	a	trial	of	rye	
bread	versus	a	low-fiber	bread	demonstrated	a	significantly	higher	
number	of	 stools	per	day	with	 rye	bread	and	 softer	 stools	 [19].	A	
meta-analysis	of	seven	placebo-controlled	trials,	published	in	2015,	
reported	that	the	relative	risk	of	treatment	success	with	fiber	was	
significantly	 higher	 (1.71;	 95%	CI	 1.20–2.42),	 stool	 frequency	was	
significantly	 increased	 (SMD	=	0.39;	95%	CI	0.03–0.76),	 and	 stool	
consistency	 improved	 (SMD	=	0.35;	 95%	CI	0.04–0.65),	 but	 again	
noted	that	the	quality	of	evidence	was	low	[20].	Both	these	system-
atic	 reviews	 identified	a	need	 for	 further	 large	placebo-controlled	
trials	of	fiber	in	CC.	With	regard	to	effect	of	fiber	supplementation	
in	differing	pathophysiological	subgroups,	 it	 is	worth	noting	that	a	








one small crossover trial comparing dried plums with psyllium in 40 
patients,	 the	number	of	CSBMs	was	significantly	higher,	and	stool	











Thus,	 it	appears	 that	 fibers	 that	alleviate	constipation	act	on	both	
the	small	and	large	intestine	to	increase	stool	water,	accelerate	tran-
sit,	and	facilitate	defecation.
Although	a	diet	 low	 in	 fermentable	carbohydrates	 (FODMAPs)	
has	been	shown	to	improve	symptoms	of	irritable	bowel	syndrome	
in	several	randomized	controlled	trials	[27,	28],	there	is	a	lack	of	con-
vincing	 evidence	 on	 its	 effectiveness	 in	 IBS-C	 specifically,	 and	 its	
impact	in	FC	has	not	been	investigated.
In	dehydrated	patients,	 increasing	fluids	will	 improve	constipa-
tion,	but	 it	 is	 important	to	recognize	that	patients	with	CC	are	not	
the same as patients with acute dehydration physiologically; an 
adequate	 fluid	 intake	 (up	 to	 2	 L/day)	will	 increase	 the	 efficacy	 of	
a	high-fiber	diet	 [29].	Overhydration	will	not	 improve	constipation	
as	 there	 is	 no	 association	 between	 fluid	 intake	 and	 constipation	
[29]	 Nevertheless,	 it	 is	 worth	 mentioning	 that	 four	 randomized,	









reduce	 symptoms	of	 constipation	 in	 the	elderly,	 but	has	not	been	
shown	to	have	any	positive	effect	on	constipation	 in	young	adults	
[31,	32].	The	minor	influence	of	physical	activity	on	bowel	function	




2.3  |  Bowel (habit) retraining




recent	 survey	 found	 that	bowel	 retraining	was	a	widely	employed	
therapeutic	strategy,	but	often	without	formal	training	of	practition-
ers	and	without	standardized	protocols	 [35].	The	 intervention	was	




Biofeedback	 is	 defined	 as	 a	 conditioning	 treatment	 where	 infor-
mation about a physiological process is converted by dedicated 
devices to a simple signal to enable the patient to learn to control 
the	disordered	defecation	process	[36].	Biofeedback	is	considered	
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appropriate	when	the	voluntary	control	of	responses	can	be	learned	
with	the	aid	of	systematic	information	about	functions	not	usually	
monitored	 at	 a	 conscious	 level	 [36].	 Initial	 open-label	 trials	 sug-
gested	that	biofeedback	was	equally	effective	in	slow-transit	consti-
pation	and	in	evacuation	disorders	[37,	38].	However,	a	subsequent	
study	 demonstrated	 that	 biofeedback	 ameliorated	 symptoms	 and	
accelerated	bowel	transit	 in	over	70%	of	slow-transit	constipation	





ecation	 including	 sham	 biofeedback,	 placebo	 pills,	 diazepam,	 and	
osmotic	laxatives	[40–42].	Improvements	in	measures	of	anorectal	















2.5  |  Transanal irrigation




been demonstrated to be superior to standard bowel care in pa-
tients	with	constipation	secondary	 to	a	neurological	disorder	 [48].	
In	these	patients,	the	use	of	TAI	improves	quality	of	life	[49],	reduces	













2.6  |  Psychological therapies





2.7  |  Areas for future research
1.	 Lifestyle	modifications	are	always	reported	as	first-line	treatment	
in	 patients	 with	 constipation,	 but	 the	 evidence	 regarding	 their	
efficacy	 is	 not	 strong.
2.	 Clinical	investigation	of	the	laxative	effect	of	magnesium	sulfate-
rich	 natural	 mineral	 waters	 is	 a	 very	 recent	 field	 of	 research.	







be	non-inferior	 to	 instrumented	biofeedback	for	 functional	def-





3  |  MANIPUL ATING THE MICROBIOME
3.1  |  Prebiotics
Prebiotics	are	defined	as	a	 substrate	 that	 is	 selectively	utilized	by	
host	 microorganisms	 conferring	 a	 health	 benefit	 [55].	 In	 another	
context,	many	of	 these	substances	are	 termed	 fermentable	oligo-,	
di-,	and	monosaccharides	and	polyols	(FODMAPs).	Compared	with	













(+0.28	 stools	 per	 day,	p	 <	 0.001),	 an	 effect	 seen	particularly	with	
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short-chain	fructans	(+0.36	stools	per	day,	p	<	0.001),	although	the	
trials	were	in	mixed	populations	of	healthy	controls	or	patients	[58].	
Fewer	 clinical	 trials	 have	 been	 performed	 investigating	 prebiotics	
specifically	 in	CC	 [58,	 59];	 a	meta-analysis	 of	 five	RCTs	 (involving	
a	mere	199	patients)	 confirmed	 that	prebiotics	 resulted	 in	 a	 small	
increase	 in	stool	frequency	 (+1.01	stools/week,	95%	CI	0.04–1.99)	









Probiotics	 are	 live	 microorganisms	 that,	 when	 administered	
in	 adequate	 amounts,	 confer	 a	 health	 benefit	 to	 the	 host	 [62].	
Unfortunately,	the	interpretation	of	available	data	on	many	probi-
otic	products	is	confounded	by	variability	in	strain	selection,	dose,	
delivery	vehicle,	 and	 limited	 information	 regarding	evaluation	of	
viability	 and	 efficacy.	 Indeed,	many	 “probiotic”	 products	 do	 not	
even	meet	the	above-stated	definition	in	that	they:	(a)	do	not	con-
tain	live	organisms	or	have	not	been	adequately	tested	to	ensure	
their	 viability	 in	 the	 conditions	 or	 for	 the	 length	 of	 time	 that	 is	
claimed,	 and/or	 (b)	 have	 not	 been	 confirmed	 to	 confer	 a	 health	
benefit	in	humans.
There	 are	 several	 animal	 and	 human	 studies	 suggesting	 that	
probiotics	may	regulate	gut	motility	and	improve	constipation-re-
lated outcomes via their impact on the gut microbiota and their 
by-products,	 and	 on	 the	 nervous	 and	 immune	 system	 [63–65].	
Systematic	 reviews	 have	 demonstrated	 variable	 results	 for	 dif-
ferent	probiotic	strains	 in	both	children	 [66,	67]	and	adults	 [68].	
A	 systematic	 review	 of	 the	 use	 of	 probiotics	 among	 the	 elderly	
with	 constipation	 showed	 a	 modest	 benefit	 for	 probiotics	 [68];	
however,	the	authors	stressed	that	caution	needs	to	be	exercised	
in	 the	 interpretation	 of	 the	 available	 data.	 Another	 systematic	
review	and	meta-analysis	 (SRMA)	of	14	RCTs	demonstrated	 that	
Bifidobacterium lactis	 species	 significantly	 increased	 stool	 fre-
quency	 (+1.5	 stools/week,	 95%	 confidence	 interval	 [CI]	 0.7–2.3)	
and	improved	symptoms	in	people	with	CC,	whereas	Lactobacillus 
casei Shirota	 did	not;	 this	 suggested	a	potential	 beneficial	 effect	
of	probiotics	 in	 constipation	 in	 favor	of	B. lactis.	However,	RCTs	
published	 subsequent	 to	 this	 systematic	 review	 have	 shown	 no	
improvement	 in	 constipation	 symptoms	 following	 the	 adminis-
tration	of	specific	B. lactis	 strains,	 including	B. lactis	HN019	that	
had been previously shown to improve constipation in a smaller 
study	 [69,	 70].	 Such	 conflicting	 data	may	 be	 attributed	 to	 study	
methodologies.	 Several	 studies	 are	 of	 low-quality	 and	 suffer	
from	 limitations	 in	 design	 and	 execution,	 including	 lack	 of	 ade-
quate	 statistical	power,	use	of	 inconsistent	diagnostic	 criteria	of	
CC,	variable	treatment	duration,	lack	of	consistency	in	outcomes,	
lack	 of	 validated	 assessment	 techniques,	 and	 selective	 outcome	












well	as	stimulating	 indigenous	bifidobacteria	and	 lactobacilli.	 In	an	
uncontrolled	pilot	study,	Valerio	and	colleagues	fed	artichokes	(con-
taining	 inulin-type	 fructans)	 and	 Lactobacillus paracasei to healthy 













3.4  |  Fecal microbiota transplantation
Fecal	microbiota	 transplantation	 (FMT)	has	also	been	 investigated	
as	a	potential	management	strategy	for	CC.	A	RCT	of	60	individu-
als	with	slow-transit	constipation	showed	that	a	significantly	higher	
proportion had 3 or more complete spontaneous bowel movements 






3.5  |  Areas for future research
1.	 Characterization	 of	 the	 colonic	 microbiome	 in	 FC	 and	 IBS-C	
with	 control	 for	 confounding	 factors.
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2.	 Does	the	baseline	microbiome	in	a	constipated	individual	predict	
response to various interventions?
3.	 High-quality	studies	of	interventions	that	modulate	the	microbi-
ome	in	FC	and	IBS-C.
4  |  MEDIC AL THER APIES
4.1  |  Laxatives
There	 are	 a	 range	 of	 laxatives	 available,	 both	 over	 the	 counter	
and	 prescribed.	 These	 are	 classified	 according	 to	 their	 primary	
mechanism	 of	 action:	 bulking	 agents	 (see	 lifestyle	 advice);	 stool	
softeners;	stimulants;	and	osmotic	agents.	Nevertheless,	despite	
being	the	mainstay	of	management	of	CC,	high-quality	clinical	tri-
als	of	 laxatives	are	scarce.	A	recent	meta-analysis	 [74]	 identified	
only	 four	 studies	 of	 laxatives	 of	 sufficient	 rigor	 and	 duration	 to	
be assessed.
A	brief	discussion	on	the	challenges	associated	with	laxative	use	




dictability	of	onset	 and	offset	of	 effect	of	 these	agents,	which	all	
depend	on	 their	 contact	 time	with	 the	mucosa	 [76].	Development	











studies	 identified	 in	 the	 above	 review	used	PEG	with	electrolytes	









difference	 between	 outcomes	with	 PEG	 or	 such	magnesium	 salts	
[81,	82].	In	IBS-C,	PEG	has	been	found	to	improve	constipation	but	
not	pain	[83].
If	 symptoms	persist,	 stimulant	 laxatives	 such	as	 senna,	bisaco-










The	 stool	 softener	 class	 of	 laxatives	 (docusate,	 liquid	 paraffin)	
has	 been	 compared	with	 osmotic	 agents	 and	 found	 to	 be	 slightly	
less	 effective	 than	 the	osmotic	 agents,	 and—especially	with	 liquid	
paraffin—be	associated	with	more	adverse	events	[84,	85].	As	such,	
they	are	more	often	used	as	adjuvant	drugs	when	patients	 report	




studies	 of	 their	 efficacy	 or	 safety.	 In	 contrast,	 three	 short-term	
(7–21	days)	controlled	studies	have	reported	the	benefit	of	potas-
sium tartrate and sodium bicarbonate suppositories in improving 
“dyschezia”	[86–88].
Clinical	 trials	 tend	to	be	short	 for	what	 is	often	a	 lifelong	con-
dition.	A	global	survey	identified	that	approximately	half	of	all	con-





Serotonin	 (5-hydroxytryptamine;	 5-HT)	 receptors	 are	 abundant	 in	
the	 gut	 and	 involved	 in	 both	motility	 and	 sensation;	 of	 these,	 the	
5-HT4 receptor has been most closely associated with the promo-
tion	of	intestinal	motility	and	transit	and	a	number	of	agonists	have	
been	developed.	The	 first	 of	 these,	 cisapride,	 an	upper	 gut	proki-
netic,	was	shown	to	have	some	efficacy	in	constipation	[91],	but	lack	
of	selectivity	and	interactions	with	the	human	ether-a-go-go-related	
gene	 (hERG)	channel	 led	 to	 the	worldwide	withdrawal	of	 the	drug	





remains	 unclear	 [92].	 Recently,	 tegaserod	was	 reintroduced	 in	 the	
United	States	for	the	treatment	of	women	with	IBS-C.
In	 contrast	 to	 cisapride	 and	 tegaserod,	 prucalopride	 is	 a	
high-affinity,	 highly	 selective	 5-HT4	 agonist	 with	 low	 affinity	
for	 the	 hERG-K⁺	 cardiac	 channels	 [95].	 This	 5-HT4	 receptor	 af-
finity	 and	 sensitivity	 confers	 greater	 efficacy	 for	 prucalopride	
and	 explains	 why	 it	 has	 not	 been	 shown	 to	 be	 arrhythmogenic	
[95].	 Prucalopride	 promotes	 colonic	motility	 and	 transit	 and	has	
been	studied	 in	 seven	 large	 (≥300	patients	 in	each),	multicenter,	
double-blind,	 placebo-controlled	 trials;	 all	 but	 one	 showed	 that	
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prucalopride	significantly	improved	bowel	function,	reduced	con-
stipation-related	 symptoms,	 and	 improved	 patient	 satisfaction	
and	constipation-related	quality	of	life	[96].	These	studies	enrolled	
patients	not	responsive	to	laxatives,	with	a	therapeutic	gain	over	
placebo	 being	 around	 20%.	 The	 most	 common	 adverse	 effects	
were	headache	(25%–30%	prucalopride;	12%–17%	placebo),	nau-








Velusetrag	 is	 another	 selective	 5-HT4 agonist that stimulates 
colonic	motility	 and	 transit,	 and	 in	 a	4-week	phase	 II	 dose-ranging	





4.3  |  Prosecretory agents
The	first	of	these	agents	was	lubiprostone,	a	bicyclic	fatty	acid	that	










for	CC	 is	 24	µg	 twice	 daily.	 Similar	 results	 have	 been	obtained	 in	
IBS-C	patients,	and	 in	 this	case,	 the	recommended	dosage	 is	8	µg	
twice	 daily	 [75].	 At	 present,	 lubiprostone	 is	 only	 available	 in	 the	
United	States,	Canada,	Switzerland,	India,	and	Japan.
The	 other	 prosecretory	 agents	 are	 guanylate	 cyclase-C	 (GC-

















Plecanatide	has	also	been	shown	 to	be	effective	 in	a	phase	 III	
study	 in	CC	and	 in	 IBS-C	 [75,	102,	103].	Similar	 to	 linaclotide,	 the	
main	adverse	effect	was	diarrhea	[102].	The	recommended	dose	is	
3	mg	daily,	but	the	drug	is	not	available	in	Europe.
4.4  |  Future therapies
It	has	been	known	for	decades	that	deconjugated	bile	salts	increase	
colonic	motility	and	secretion	and,	if	present	in	excessive	amounts,	


















transporter	 1	 (SGLT1)	 inhibitor	 that	 increases	 luminal	 glucose	 and	
water.	This	has	also	demonstrated	efficacy	in	CC	in	a	phase	II	study;	
diarrhea and abdominal distension were the most notable adverse 
effects	[108].
4.5  |  Areas for future research
1.	 While	 there	 are	 now	 a	 number	 of	 prescription	 drug	 options	
in	 FC	 and	 IBS-C,	 their	 relative	 efficacy	 is	 unknown	 and	 com-
parative studies between these medications and against more 






4.	 Constipation	 sufferers	 frequently	 complain	of	developing	 toler-
ance	to	various	medications—the	true	nature	of	this	phenomenon	
and	its	management	deserve	further	investigation.
8 of 15  |     CORSETTI ET al.
5  |  SURGIC AL OPTIONS
The	 role	 of	 surgery	 is	 governed	 by	 establishing	 the	 dominant	
pathophysiology	 in	 terms	 of	 symptom	 generation.	 Surgery	 has	 a	
role	 in	 patients	 with	 refractory	 constipation	 associated	with	 co-
lonic	inertia,	when	this	is	not	part	of	a	panenteric	motility	disorder.	
Surgery	 also	 has	 a	 role	 in	 the	 correction	of	 pelvic	 floor	 prolapse	
where	 it	 is	deemed	 to	be	causing	symptoms.	However,	given	 the	
risk	of	potential	harm	and	 irreversibility	of	most	procedures,	 sur-
gery should only be considered when all conservative measures 
have	failed	[109].














the procedure with the greatest supporting evidence (observational 
only,	but	>50	published	series).	Segmental	colonic	resection	may	be	
considered	 if	 there	are	concerns	about	diarrhea	and	 incontinence;	
however,	 this	will	 involve	a	trade-off	with	a	higher	risk	of	ongoing	
constipation	[110].




validated	 questionnaires	 [111].	 Complications	 occurred	 in	 ap-
proximately	 24%	 of	 patients.	 Recurrent	 episodes	 of	 small	 bowel	
obstruction	 occurred	 in	 about	 15%	 of	 patients	 in	 the	 long	 term,	
with	significant	burden	of	rehospitalization	and	frequent	recourse	
to	 further	 surgery	 [111].	 Patients	 may	 also	 experience	 diarrhea,	






Relative	 contraindications	 to	 colectomy	 include	 the	 following:	
major	 upper	GI	 symptoms	 (proven	dysmotility	 is	 an	 absolute	 con-
traindication)	 [111];	 significant	 abdominal	 pain	 and	 bloating;	 and	
poor	anal	sphincter	function.	Such	findings	push	more	strongly	to-
ward	 ileostomy	 rather	 than	 resection.	 An	 untreated	 concomitant	
evacuation	 disorder	 [111]	 is	more	 controversial,	 although	 there	 is	
agreement	 that	management	should	 initially	 focus	on	 treating	 this	
rather than by resecting the colon.
5.2  |  Sacral neuromodulation
Sacral	neuromodulation	 (SNM)	 is	an	established	 treatment	 for	pa-




creased	 episodes	 of	 successful	 defecation,	 reduction	 in	 sensation	




Two	 subsequent	 randomized,	 double-blinded,	 crossover	 stud-
ies	have	shown	no	significant	difference	between	sham	and	active	











spina	 bifida	 or	 slow-transit	 constipation	 [118];	 however,	 adults	
and patients with colonic dysmotility have lower published suc-
cess	 rates	 [118].	 Stoma	 stenosis	 is	 common	 in	 adults	 and	 often	
requires	surgical	revision	[118].	In	patients	with	refractory	slow-
transit	 constipation,	 an	 (ACE)	 conduit	 is	 an	 alternative	 to	 loop	









stoma complications are common and reintervention may be neces-
sary;	however,	up	to	70%	of	patients	are	satisfied	with	the	interven-
tion,	despite	a	20%	reoperation	rate	[120].
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5.6  |  Rectal excisional procedures
Transanal	 resection	of	 intussuscepting	 rectal	wall	with	 or	without	
rectocele	resection	may	be	achieved	by	the	STARR	(stapled	transa-
nal	rectal	resection)	procedures.	A	recent	SRMA	identified	47	stud-








of	 patients.	 These	 outcomes	 have	 reduced	 its	 former	 popularity.	
Recurrent	prolapse	occurred	in	4.3%	of	patients.





gical	 approaches	 (vaginal,	 perineal,	 and	 anal).	 Seventy-eight	 percent	
of	patients	reported	a	satisfactory	or	good	outcome,	with	30%–50%	









5.8  |  Areas for future research
1.	 The	 evidence	 base	 relating	 to	 surgical	 options	 for	 those	 with	
refractory	 constipation	 remains	 slim	 and	 suffers	 from	 many	
limitations.	 High-quality	 prospective	 studies	 are	 needed:
a.	 To	 guide	 optimal	 patient	 selection	 for	 colectomy	 or	 pelvic	
floor/anorectal	interventions











induced	constipation	 is	not	 included	 in	 this	algorithm)	as	 reported	
in	Panel	A.
The	information	collected	during	clinical	evaluation	then	guides	
the	 selection	 of	 appropriate	 medications,	 with	 preference	 ideally	
given	to	those	with	proven	efficacy	in	placebo-controlled	clinical	tri-
als	(Panel	B).	In	this	respect,	it	is	important	to	consider	the	spectrum	
of	 symptom	 presentation	 and	 review	 the	 response	 to	 each	 treat-
ment.	It	is	indeed	known	that	in	IBS-C,	some	medications	(e.g.,	PEG)	





further	 investigations.	 Medications	 with	 complementary	 mecha-
nisms	of	action	(ie,	osmotic	laxative	or	secretagogue	with	a	stimulant	
laxative	or	prokinetic)	can	be	combined.
In	 the	 absence	 of	 an	 internationally	 recognized	 definition	 of	





pelvic	 floor	 biofeedback	 therapy.”	 The	 4-week	 criterion	 was	 cho-
sen in recognition that most patients who respond to medications 
for	CC	generally	do	so	within	4	weeks,	and	this	 is	also	reflected	 in	
NICE	guidance	 [53].	 In	 that	publication,	 the	use	of	 a	yet-to-be	val-
idated	 clinical	 decision-making	 tool	 was	 proposed	 [53].	 However,	
the	 result	 of	 a	 recent	 study	 suggests	 that	 the	modified	 version	 of	
the	Patient	Assessment	of	Constipation-Symptom	could	better	cap-
ture	the	complex	and	multifactorial	patient's	response	to	treatment	
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when to consider surgical options
Constipation
Alarm features




Medical history, physical examination and DRE
No alarm features
Identify lifestyle factors and potential
secondary causes of constipation 
(including opioid-induced 









PEG (1-2 sachets daily)
Combine with bisacodyl or picosulfate
(5 mg 1-2 tablets daily or suppositories)
Switch to prucalopride 1-2 mg daily, or 
combine with laxatives
No Yes
Review lifestyle modification (fibre, fluid, exercise, probiotics)*
Linaclotide 290 µg or other 
secretagogues
Questions to better characterise 
constipation
Duration of treatment 
before declaring a 
failure: 4-8 weeks
What do you mean by constipation?
Infrequent bowel movements,difficult defecation or
both? How many bowel movement per
week/month? What Bristol Stool Form?
Panel (B)
Linaclotide 145 µg or other secretagogues
Pain relieved/related to defecation suggests
IBS-C; pain/doscomfort presents after many
days of no bowel movements can occurr in FC
In IBS-C, consider
antispasmodics or 
neuromodulators in case 
constipation improves but
abdominal pain persists
and is dominant symptom
FC IBS-C Patient can move between FC and IBS-C over
time
Anorectal function testing (balloon 
expulsion test, defecography, rectal 




alternative according to local 
expertise
Colonic / whole gut transit
+/- defaecography*
+/- adjunctive tests e.g. 
urodynamics








investigation correlation to focus on 
further pharmacology (panel B) or 
other untried interventions  
MDT to discuss surgical




Obvious clinical evidence of 
overt pelvic organ prolapse 1
MDT to discuss surgical 
options and alternative 
management strategies 
Generalised slow transit 
constipation without absolute and 




Rectocele repair via transvaginal or 
transanal route +/- adjuncts 1
Posterior compartment prolapse 
syndrome with high grade 
intussusception +/- rectocoele
Consider laparoscopic ventral 
rectopexy or alternative e.g. 
STARR +/- adjuncts 1
Colectomy and ileo-rectal 
anastomosis
Posterior compartment prolapse 
syndrome with dominant rectocele 
+/- intussusception
No surgical target defined
Discuss alternatives after re-
focussed discussion including
transanal irrigation, untried 
behavioural interventions and 
combined medications
Relief of symptoms 
with ileostomy but 
does not want 
permanent stoma













defecation	disorder	may	 reflect	 problems	of	 coordination	 (addressed	
predominantly	by	classical	biofeedback),	muscle	weakness	(addressed	
mainly	by	pelvic	floor	muscle	therapy),	and	rectal	sensation	(addressed	
in	 some	 centers	 by	 sensory	 forms	 of	 biofeedback)	 or	 combinations	
thereof.	Although	unsupported	by	RCT	evidence,	 transanal	 irrigation	
is	a	further	option	[47].	The	evaluation	of	anorectal	function	can	also	
be considered earlier in the pathway in centers that have easy access 
to	these	 investigations	and	biofeedback.	Evaluation	of	colonic/whole	
gut	transit	can	be	used	to	further	define	underlying	pathophysiology.
However,	 all	 investigations	 have	 some	 limitations	 as	 recently	
pointed	out	[131,	132].	It	is	therefore	important	that	the	results	of	
diagnostic	testing	are	considered	in	the	context	of	the	“holistic”	clin-








ies	 internationally	 but	 should	 clearly	 include	 colorectal	 surgeon(s)	
with	appropriate	expertise.	This	approach	will	only	be	relevant	in	a	
minority	of	patients	with	constipation.
For	 patients	 considered	 for	 surgical	 intervention,	 all	 information	
from	 comprehensive	 assessment	 (symptoms,	 physical	 examination,	
and	 investigations)	 are	 synthesized,	 previous	 treatments	 reviewed,	
and	all	other	factors	that	might	influence	surgical	decision	making	con-




The	MDT	must	 distinguish	 patients	with	 a	modifiable	 surgical	
target	from	those	in	whom	there	is	no	detectable	or	surgically	cor-
rectable	 anomaly,	 and	 those	 unsuitable	 for	 intervention	 for	 other	
reasons	 (e.g.,	 high	 surgical	 risk).	 The	 presence	 of	 substantial	 un-
derlying psychological or behavioral issues should also be assessed 
systematically,	 as	 these	 factors	 are	 a	 relative	 contraindication	 to	
surgery.	In	practice,	two	main	patient	groups	may	be	considered	for	
surgical	 intervention	based	on	 target	 pathophysiology,	 those	with	
slow-transit	constipation	unresponsive	to	non-surgical	interventions	
and	those	with	significant	posterior	compartment	prolapse.
6.1  |  Areas for future research
1.	 Critically	 evaluate	 the	 feasibility	 of	 this	 algorithm	 in	 everyday	
clinical practice
2.	 Measure	 its	 implementation	 and	 resultant	 impact	 on	 patient	
outcomes.
7  |  CONCLUSIONS
The	 literature	 accumulated	over	 the	 last	10	years	on	CC	manage-
ment has certainly added important evidence to guide clinical prac-
tice.	Biofeedback	has	been	recognized	as	valuable	treatment	option	
for	 functional	 defecation	 disorders,	 some	 pharmacological	 treat-
ments	have	been	demonstrated	to	be	more	effective	than	placebo,	
and	the	surgical	literature	has	been	extensively	reviewed	to	identify	
gaps	 in	 the	 current	 knowledge.	 In	 contrast,	 there	 are	 some	 areas	
where	systematic	review	of	the	literature	still	reveals	uncertainties,	
as	reported	in	the	areas	for	future	research	paragraphs.
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